Company Profile for Nuvera Biosciences.Nuvera Biosciences Corporate Summary Nuvera Biosciences is developing molecular diagnostic tests that will help significantly improve treatment selection and quality of patient management in cancer. The Company has developed of four gene-based breast cancer tests for determining individual patient response to standard-of-care therapy. The tests have been clinically validated with trials at MD Anderson Cancer Center, a founding partner and other leading cancer centers worldwide. Breast Cancer Tests for Therapy Selection It is commonly known among oncologists that, although multiple treatment options are available for cancer management, not every patient responds well to therapy and given broadly, response to therapy remains modest. Breast cancer has an annual incidence of over 200,000 in the US and 1.2 million worldwide, and benefits from the availability of several approved standard-of-care therapies for common use. However, the therapies widely differ in cost, toxicity toxicity /tox·ic·i·ty/ (tok-sis´i-te) the quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. , and how a patient's tumor tumor: see neoplasm. responds to them specifically. There is no test currently that differentiates likely response among available standard therapies for an individual patient's tumor. Two tests developed by Nuvera select breast cancer patients who are excellent responders to taxane-based chemotherapy and to endocrine endocrine /en·do·crine/ (en´do-krin, en´do-krin) 1. secreting internally. 2. pertaining to internal secretions; hormonal. See also under system. en·do·crine adj. therapy, respectively. The tests are aimed at helping treatment decisions directed at achieving long-term patient survival. Nuvera is commercializing these diagnostic tests with Veridex, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control for offering within a reference laboratory using microarray See micro array. microarray - A technique for performing many DNA experiments in parallel. Nothing to do with computers. gene chips. The results will report whether the patient is likely to respond to (i) standard taxane-based chemotherapy, and (ii) standard hormonal therapy Hormonal therapy Use of hormone medications to inhibit menstruation and relieve the symptoms of endometriosis. Mentioned in: Endometriosis such as tamoxifen tamoxifen (təmŏk`sĭfĕn'), synthetic hormone used in the treatment of breast cancer. Introduced in 1978, tamoxifen is used to prevent recurrences of cancer in women who have already undergone surgery to remove their tumors. . Two additional tests can report status of the Her2/neu receptor and the estrogen receptor estrogen receptor A protein of a superfamily of nuclear receptors for small hydrophilic ligands–eg, steroid hormones, thyroid hormone, vitamin D, retinoids; the presence of ERs in breast CA generally is associated with a better prognosis, as they respond to (ER). MD Anderson will perform clinical testing using these tests under an approved trial that will allow assignment of therapy based on results of the diagnostic assays Noun 1. diagnostic assay - an assay conducted for diagnostic purposes diagnostic test assay - a quantitative or qualitative test of a substance (especially an ore or a drug) to determine its components; frequently used to test for the presence or . Other leading cancer centers are being signed up for studies leading to test adoption.
Company: < < <
Nuvera Biosciences
< < <
Headquarters Address: < < <
400 West Cummings Park
< < <
Suite 5350
< < <
Woburn, MA 01801
< < <
Main Telephone: < < <
781.938.3830
< < <
Type of Organization: < < <
Private
< < <
Industry: < < <
Biotechnology
< < <
Key Executives: < < <
CEO: Nandan Padukone
< < <
Public Relations < < <
Contact: < < <
Hepzi Fonseca
Phone: < < <
781.572.2485
Email: < < <
hepzi@nuverabio.com
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion